Alto Neuroscience Files S-1 for IPO, Eyes Public Market Debut

TL;DR

**Alto Neuroscience is going public, S-1 filed January 12, 2024.**

AI Summary

Alto Neuroscience, Inc. filed an S-1 registration statement on January 12, 2024, for a proposed initial public offering (IPO) of its securities. The company, based in Los Altos, CA, and led by President and CEO Amit Etkin, M.D., Ph.D., is seeking to raise capital to fund its operations as a pharmaceutical preparations company. This filing is crucial for potential investors as it provides the first comprehensive look into the company's financials, business model, and risks before its shares become publicly traded.

Why It Matters

This S-1 filing signals Alto Neuroscience's intent to go public, offering investors a chance to buy shares in a new pharmaceutical company. It's the first detailed look at their business before trading begins.

Risk Assessment

Risk Level: high — As a pharmaceutical company in its early stages of public offering, Alto Neuroscience faces significant risks related to drug development, regulatory approvals, and market acceptance.

Analyst Insight

Investors should closely review the full S-1 filing for Alto Neuroscience, Inc. to understand its financial health, drug pipeline, and competitive landscape before making any investment decisions once the IPO is priced.

Key Numbers

• 0001999480 — Central Index Key (CIK) (Unique identifier for Alto Neuroscience, Inc. with the SEC)
• 2834 — Standard Industrial Classification (SIC) (Indicates the company operates in 'Pharmaceutical Preparations')
• 834210124 — IRS Employer Identification Number (EIN) (Tax identification number for Alto Neuroscience, Inc.)
• 51 — Public Document Count (Number of documents included in this S-1 filing)
• 773-255-5012 — Business Phone Number (Primary contact number for Alto Neuroscience, Inc.)

Key Players & Entities

• Alto Neuroscience, Inc. (company) — the registrant filing the S-1
• Amit Etkin, M.D., Ph.D. (person) — President and Chief Executive Officer of Alto Neuroscience, Inc.
• Nicholas Smith (person) — Chief Financial Officer of Alto Neuroscience, Inc.
• Cooley LLP (company) — legal counsel for Alto Neuroscience, Inc.
• Latham & Watkins LLP (company) — legal counsel involved in the filing
• January 12, 2024 (date) — date of S-1 filing
• 333-276495 (dollar_amount) — SEC File Number for the registration statement

Forward-Looking Statements

• Alto Neuroscience, Inc. will complete its initial public offering (IPO) (Alto Neuroscience, Inc.) — medium confidence, target: Q2 2024
• The company will use the proceeds from the IPO to advance its pharmaceutical pipeline (Alto Neuroscience, Inc.) — high confidence, target: Q4 2024

FAQ

From the Filing

0001193125-24-007592.txt : 20240112 0001193125-24-007592.hdr.sgml : 20240112 20240112165010 ACCESSION NUMBER: 0001193125-24-007592 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 51 FILED AS OF DATE: 20240112 DATE AS OF CHANGE: 20240112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-276495 FILM NUMBER: 24532613 BUSINESS ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 369 SOUTH SAN ANTONIO RD. CITY: LOS ALTOS STATE: CA ZIP: 94022 S-1 1 d204454ds1.htm S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on January 12, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Alto Neuroscience, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 83-4210124 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos, CA 94022 Tel: (650) 200-0412 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Amit Etkin, M.D., Ph.D. President and Chief Executive Officer Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos, CA 94022 Tel: (650) 200-0412 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies to: Divakar Gupta Christina T. Roupas Courtney M.W. Tygesson Laurie Bauer Cooley LLP 110 North Wacker Drive Suite 4200 Chicago, IL 60606 Tel: (312) 881-6500 Nicholas Smith Chief Financial Officer Alto Neuroscience, Inc. 369 South San Antonio Road Los Altos, CA 94022 Tel: (650) 200-0412 Nathan Ajiashvili Christopher Lueking Ross McAloon Latham & Watkins LLP 1271 Avenue of the Americas New York, NY 10020 Tel: (212) 906-1200 Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐ If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by chec